Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

180
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
180
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

233
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
233
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

151
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
151
Types of Hypothesis Testing01:11

Types of Hypothesis Testing

26.6K
There are three types of hypothesis tests: right-tailed, left-tailed, and two-tailed.
When the null and alternative hypotheses are stated, it is observed that the null hypothesis is a neutral statement against which the alternative hypothesis is tested. The alternative hypothesis is a claim that instead has a certain direction. If the null hypothesis claims that p = 0.5, the alternative hypothesis would be an opposing statement to this and can be put either p > 0.5, p < 0.5, or p...
26.6K
Multiple Comparison Tests01:13

Multiple Comparison Tests

4.0K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
4.0K
Relative Risk01:12

Relative Risk

262
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
262

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity.

Cancers·2026
Same author

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

CA: a cancer journal for clinicians·2026
Same author

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Modeling the age-specific incidence of mild cognitive impairment incorporating the time-varying relationship of Alzheimer's disease biomarkers over 28 years.

Journal of Alzheimer's disease : JAD·2025
Same author

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.

Nature medicine·2025
Same author

Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Aug 3, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Simultaneous hypothesis testing for multiple competing risks in comparative clinical trials.

Jiyang Wen1, Mei-Cheng Wang1, Chen Hu1,2

  • 1Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Statistics in Medicine
|April 10, 2023
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for analyzing competing risks in clinical trials, offering better insights into multiple outcomes like death or discharge in COVID-19 patients. The approach improves risk estimates and conclusions for complex health events.

Keywords:
COVID-19clinical trialscompeting riskscumulative incidencemultiple endpointsrestricted mean time

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

312

Related Experiment Videos

Last Updated: Aug 3, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

312

Area of Science:

  • Biostatistics
  • Clinical Trials Methodology
  • Epidemiology

Background:

  • Competing risks are common in clinical studies, and ignoring them biases survival analysis.
  • Traditional methods inadequately handle multiple competing events of equal clinical importance.
  • COVID-19 trials exemplify situations with multiple, equally significant outcomes (e.g., death, discharge).

Purpose of the Study:

  • To develop nonparametric estimation and simultaneous inference methods for multiple cumulative incidence functions (CIFs).
  • To extend these methods for analyzing restricted mean times across multiple endpoints.
  • To provide a robust analytical framework for studies with multiple, clinically relevant competing risks.

Main Methods:

  • Developed nonparametric estimation techniques for multiple CIFs.
  • Introduced simultaneous inferential methods for these CIFs.
  • Incorporated restricted mean time calculations for comprehensive endpoint analysis.
  • Validated methods using Monte Carlo simulations and a COVID-19 clinical trial dataset.

Main Results:

  • The proposed method accurately estimates multiple cumulative incidence functions.
  • Simultaneous inference provides reliable comparisons across various endpoints.
  • Restricted mean times were effectively estimated for each competing event.
  • The analysis demonstrated global insights into treatment effects across multiple endpoints in COVID-19 trials.

Conclusions:

  • The developed nonparametric approach effectively handles multiple competing risks in survival analysis.
  • This method offers superior insights into treatment effects across diverse clinical endpoints compared to traditional approaches.
  • The findings are crucial for interpreting complex outcomes in clinical trials, particularly during pandemics like COVID-19.